Lessons Learned from Pharmaceutical Nanomaterials - Safety of Nanomaterials along Their Lifecycle - page 130

Cahill, P. A., A. W. Knight, N. Billinton, M. G. Barker, L. Walsh, P. O. Keenan, C. V. Williams,
D. J. Tweats, and R. M. Walmsley (2004) The GreenScreen genotoxicity assay: A screen-
ing validation programme. Mutagenesis 19 (2):105-119.
Carr, B. and A. Malloy (2006) NanoParticle Tracking Analysis-The Nanosight System:1-73.
Cleland, J. L., A. Daugherty, and R. Mrsny (2001) Emerging protein delivery methods. Curr
Opin Biotechnol 12 (2):212-219.
Collnot, E. M., H. Ali, and C. M. Lehr (2012) Nano- and microparticulate drug carriers for
targeting of the inflamed intestinal mucosa. J Control Release 161 (2):235-246.
Cooper, A. (2004) Measuring Zeta Potential using Laser Doppler Electrophoresis. Malvern
Technical Note :1-2.
Crouch, S., R. Kozlowski, K. Slater, and J. Fletcher. (1993) The use of ATP bioluminescence
as a measure of cell proliferation and cytotoxicity. J Immunol Methods 160 (1):81-88.
Davis, M. E (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclo-
dextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6 (3):659-68.
Davis, M. E., Z. G. Chen, and D. M. Shin (2008) Nanoparticle therapeutics: An emerging
treatment modality for cancer. Nat Rev Drug Discov 7 (9):771-782.
Davis, M. E., J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D.
Heidel, and A. Ribas (2010) Evidence of RNAi in humans from systemically adminis-
tered siRNA via targeted nanoparticles. Nature 464 (7291):1067-1070.
Desai, N., V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes,
P. Noker, R. Yao, E. Labao, M. Hawkins, and P. Soon-Shiong (2006) Increased anti-
tumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of
cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based
paclitaxel. Clin Cancer Res 12 (4):1317-1324.
Ellman, G. L. (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82 (1):70-77.
Filipe, V., A. Hawe, and W. Jiskoot (2010) Critical evaluation of Nanoparticle Tracking
Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggre-
gates. Pharm Res 27 (5):796-810.
Geiser, M. and W. G. Kreyling (2010) Deposition and biokinetics of inhaled nanoparticles.
Part Fibre Toxicol 7 (2):1-17.
Gene Silencing News | RNAi | GenomeWeb (2013) Available from http://www.genomeweb.
com/rnai/roche-delivery- tech-advancing-arrowhead-drops-first-generation-cancer-drug
(accessed last on 10.07.14).
Gradishar, W. J., S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and
J. O'Shaughnessy (2005) Phase III trial of nanoparticle albumin-bound paclitaxel com-
pared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin
Oncol 23 (31):7794-7803.
Grobelny, J., F. Del Rio, N. Pradeep, and D. I. Kim (2009) Size measurement of nanoparticles
using atomic force microscopy. NIST-NCL Method PCC-6 .
Habeeb, A. F. (1966) Determination of free amino groups in proteins by trinitrobenzenesul-
fonic acid. Anal Biochem 14 (3):328-336.
Hasenberg, M., S. Stegemann-Koniszewski, and M. Gunzer (2013) Cellular immune reactions
in the lung. Immunol Rev 251 (1):189-214.
Hatakeyama, H., E. Ito, M. Yamamoto, H. Akita, Y. Hayashi, K. Kajimoto, N. Kaji, Y. Baba, and
H. Harashima (2011) A DNA microarray-based analysis of the host response to a nonviral
gene carrier: A strategy for improving the immune response. Mol Ther 19 (8):1487-198.
Hawkins, M. J., P. Soon-Shiong, and N. Desai (2008) Protein nanoparticles as drug carriers in
clinical medicine. Adv Drug Deliv Rev 60 (8):876-885.
Ibrahim, N. K., N. Desai, S. Legha, P. Soon-Shiong, R. L. Theriault, E. Rivera, B. Esmaeli,
S. E. Ring, A. Bedikian, G. N. Hortobagyi, and J. A. Ellerhorst (2002) Phase I and
pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle
formulation of paclitaxel. Clin Cancer Res 8 (5):1038-1044.